Differential pharmacology and clinical utility of long-acting bronchodilators in COPD – focus on olodaterol
Maria Gabriella Matera,1 Josuel Ora,2 Mario Cazzola2,3 1Department of Experimental Medicine, Unit of Pharmacology, Second University of Naples, Naples, 2Division of Respiratory Medicine, University Hospital Tor Vergata, 3Department of Systems Medicine, Respiratory Pharmacology Research Unit, Univer...
Main Authors: | Matera MG, Ora J, Cazzola M |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2015-12-01
|
Series: | Therapeutics and Clinical Risk Management |
Subjects: | |
Online Access: | https://www.dovepress.com/differential-pharmacology-and-clinical-utility-of-long-acting-bronchod-peer-reviewed-article-TCRM |
Similar Items
-
Striving for optimal bronchodilation: focus on olodaterol
by: Incorvaia C, et al.
Published: (2016-03-01) -
Prevention of copd exacerbations. Focus on dual bronchodilators
by: V. V. Arkhipov
Published: (2018-10-01) -
Olodaterol exerts anti-inflammatory effects on COPD airway epithelial cells
by: Nan Yang, et al.
Published: (2021-02-01) -
Pharmacokinetics and safety of olodaterol administered with the Respimat Soft Mist inhaler in subjects with impaired hepatic or renal function
by: Kunz C, et al.
Published: (2016-03-01) -
Superiority of tiotropium plus olodaterol in comparison with salmeterol plus fluticasone
by: Tamura T, et al.
Published: (2016-11-01)